Free tool
Stocks listed on Nasdaq GM
We cover 44 companies listed on Nasdaq GM. The median market value in the group is $3.56B. Across the group, the median move over the past trading day is −0.25%. 82% of the 44 with a 200-day average trade above it. Price change over the past year runs from −8.9% to +279.2% across the middle 80 percent of the group, with a median of +65.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
44 of 701 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% |
| AXSM | Axsome Therapeutics, Inc. | $10.85B | Large cap | +69.99% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
| ABVX | ABIVAX Société Anonyme | $10.17B | Large cap | +46.70% |
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| XENE | Xenon Pharmaceuticals Inc. | $6.18B | Mid cap | +64.11% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +7.27% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.74B | Mid cap | +80.92% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | +10.65% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +159.74% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +11.97% |
| TMDX | TransMedics Group, Inc. | $3.19B | Mid cap | −21.43% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| VERA | Vera Therapeutics, Inc. | $2.65B | Mid cap | +67.21% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.61B | Mid cap | −0.42% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +321.09% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| OCUL | Ocular Therapeutix, Inc. | $2.37B | Mid cap | −12.58% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
| ADMA | ADMA Biologics, Inc. | $2.16B | Mid cap | −44.17% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.